JP2018070614A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2018070614A5 JP2018070614A5 JP2017212845A JP2017212845A JP2018070614A5 JP 2018070614 A5 JP2018070614 A5 JP 2018070614A5 JP 2017212845 A JP2017212845 A JP 2017212845A JP 2017212845 A JP2017212845 A JP 2017212845A JP 2018070614 A5 JP2018070614 A5 JP 2018070614A5
- Authority
- JP
- Japan
- Prior art keywords
- alkyl
- ring
- hydrogen
- pharmaceutically acceptable
- acceptable salt
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 125000000217 alkyl group Chemical group 0.000 claims 56
- 229910052739 hydrogen Inorganic materials 0.000 claims 21
- 239000001257 hydrogen Substances 0.000 claims 21
- 150000001875 compounds Chemical class 0.000 claims 19
- 150000002431 hydrogen Chemical class 0.000 claims 19
- 150000003839 salts Chemical class 0.000 claims 19
- 239000012453 solvate Substances 0.000 claims 18
- 229910052799 carbon Inorganic materials 0.000 claims 16
- 239000000651 prodrug Substances 0.000 claims 15
- 229940002612 prodrug Drugs 0.000 claims 15
- 229910052760 oxygen Inorganic materials 0.000 claims 14
- 229910052717 sulfur Inorganic materials 0.000 claims 14
- 229910052736 halogen Inorganic materials 0.000 claims 13
- 150000002367 halogens Chemical class 0.000 claims 13
- 229910052757 nitrogen Inorganic materials 0.000 claims 8
- 125000000392 cycloalkenyl group Chemical group 0.000 claims 7
- 125000000753 cycloalkyl group Chemical group 0.000 claims 7
- 125000000623 heterocyclic group Chemical group 0.000 claims 7
- 239000008194 pharmaceutical composition Substances 0.000 claims 7
- 125000003118 aryl group Chemical group 0.000 claims 6
- 229920006395 saturated elastomer Polymers 0.000 claims 6
- 125000001072 heteroaryl group Chemical group 0.000 claims 5
- 101100294106 Caenorhabditis elegans nhr-3 gene Proteins 0.000 claims 4
- 208000020358 Learning disease Diseases 0.000 claims 3
- 125000004432 carbon atom Chemical group C* 0.000 claims 3
- 201000003723 learning disability Diseases 0.000 claims 3
- 208000000044 Amnesia Diseases 0.000 claims 2
- 208000019838 Blood disease Diseases 0.000 claims 2
- YZCKVEUIGOORGS-OUBTZVSYSA-N Deuterium Chemical compound [2H] YZCKVEUIGOORGS-OUBTZVSYSA-N 0.000 claims 2
- 208000026139 Memory disease Diseases 0.000 claims 2
- 208000031888 Mycoses Diseases 0.000 claims 2
- 230000007000 age related cognitive decline Effects 0.000 claims 2
- 208000010877 cognitive disease Diseases 0.000 claims 2
- 230000001149 cognitive effect Effects 0.000 claims 2
- 230000007547 defect Effects 0.000 claims 2
- 230000006735 deficit Effects 0.000 claims 2
- 229910052805 deuterium Inorganic materials 0.000 claims 2
- 208000014951 hematologic disease Diseases 0.000 claims 2
- 208000018706 hematopoietic system disease Diseases 0.000 claims 2
- 230000006984 memory degeneration Effects 0.000 claims 2
- 208000023060 memory loss Diseases 0.000 claims 2
- 239000000203 mixture Substances 0.000 claims 2
- 208000028173 post-traumatic stress disease Diseases 0.000 claims 2
- 125000006552 (C3-C8) cycloalkyl group Chemical group 0.000 claims 1
- 208000024893 Acute lymphoblastic leukemia Diseases 0.000 claims 1
- 208000014697 Acute lymphocytic leukaemia Diseases 0.000 claims 1
- 208000031261 Acute myeloid leukaemia Diseases 0.000 claims 1
- 208000036762 Acute promyelocytic leukaemia Diseases 0.000 claims 1
- 208000024827 Alzheimer disease Diseases 0.000 claims 1
- 208000019901 Anxiety disease Diseases 0.000 claims 1
- 208000006096 Attention Deficit Disorder with Hyperactivity Diseases 0.000 claims 1
- 208000036864 Attention deficit/hyperactivity disease Diseases 0.000 claims 1
- 206010003805 Autism Diseases 0.000 claims 1
- 208000020706 Autistic disease Diseases 0.000 claims 1
- 208000032791 BCR-ABL1 positive chronic myelogenous leukemia Diseases 0.000 claims 1
- 208000020925 Bipolar disease Diseases 0.000 claims 1
- -1 CF 3 Chemical class 0.000 claims 1
- 208000010833 Chronic myeloid leukaemia Diseases 0.000 claims 1
- 208000028698 Cognitive impairment Diseases 0.000 claims 1
- 206010010904 Convulsion Diseases 0.000 claims 1
- 206010017533 Fungal infection Diseases 0.000 claims 1
- 206010019196 Head injury Diseases 0.000 claims 1
- 208000023105 Huntington disease Diseases 0.000 claims 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims 1
- 208000009829 Lewy Body Disease Diseases 0.000 claims 1
- 201000002832 Lewy body dementia Diseases 0.000 claims 1
- 201000003793 Myelodysplastic syndrome Diseases 0.000 claims 1
- 208000033761 Myelogenous Chronic BCR-ABL Positive Leukemia Diseases 0.000 claims 1
- 208000033776 Myeloid Acute Leukemia Diseases 0.000 claims 1
- 206010028980 Neoplasm Diseases 0.000 claims 1
- 208000021384 Obsessive-Compulsive disease Diseases 0.000 claims 1
- 208000006664 Precursor Cell Lymphoblastic Leukemia-Lymphoma Diseases 0.000 claims 1
- 208000033826 Promyelocytic Acute Leukemia Diseases 0.000 claims 1
- 208000006289 Rett Syndrome Diseases 0.000 claims 1
- 206010041250 Social phobia Diseases 0.000 claims 1
- 201000004810 Vascular dementia Diseases 0.000 claims 1
- 239000004480 active ingredient Substances 0.000 claims 1
- 125000003342 alkenyl group Chemical group 0.000 claims 1
- 125000004429 atom Chemical group 0.000 claims 1
- 208000015802 attention deficit-hyperactivity disease Diseases 0.000 claims 1
- 230000003542 behavioural effect Effects 0.000 claims 1
- 230000008033 biological extinction Effects 0.000 claims 1
- 201000011510 cancer Diseases 0.000 claims 1
- 150000001721 carbon Chemical group 0.000 claims 1
- 239000011203 carbon fibre reinforced carbon Substances 0.000 claims 1
- 239000003795 chemical substances by application Substances 0.000 claims 1
- 238000009225 cognitive behavioral therapy Methods 0.000 claims 1
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 claims 1
- 230000007812 deficiency Effects 0.000 claims 1
- 201000010099 disease Diseases 0.000 claims 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 206010013932 dyslexia Diseases 0.000 claims 1
- 230000008434 fear extinction Effects 0.000 claims 1
- 230000014061 fear response Effects 0.000 claims 1
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims 1
- 208000013403 hyperactivity Diseases 0.000 claims 1
- 208000035231 inattentive type attention deficit hyperactivity disease Diseases 0.000 claims 1
- 208000027866 inflammatory disease Diseases 0.000 claims 1
- 238000000185 intracerebroventricular administration Methods 0.000 claims 1
- 206010027175 memory impairment Diseases 0.000 claims 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 1
- 230000001613 neoplastic effect Effects 0.000 claims 1
- 210000002569 neuron Anatomy 0.000 claims 1
- 201000001119 neuropathy Diseases 0.000 claims 1
- 230000007823 neuropathy Effects 0.000 claims 1
- 208000019906 panic disease Diseases 0.000 claims 1
- 208000033808 peripheral neuropathy Diseases 0.000 claims 1
- 239000008024 pharmaceutical diluent Substances 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- 230000002265 prevention Effects 0.000 claims 1
- 238000001671 psychotherapy Methods 0.000 claims 1
- 238000011084 recovery Methods 0.000 claims 1
- 201000000980 schizophrenia Diseases 0.000 claims 1
- 208000007056 sickle cell anemia Diseases 0.000 claims 1
- 201000006152 substance dependence Diseases 0.000 claims 1
- 208000011117 substance-related disease Diseases 0.000 claims 1
- 230000000946 synaptic effect Effects 0.000 claims 1
- 230000003956 synaptic plasticity Effects 0.000 claims 1
- 208000011580 syndromic disease Diseases 0.000 claims 1
- 238000002560 therapeutic procedure Methods 0.000 claims 1
- 230000000472 traumatic effect Effects 0.000 claims 1
- 210000001215 vagina Anatomy 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201161480133P | 2011-04-28 | 2011-04-28 | |
| US61/480,133 | 2011-04-28 | ||
| JP2014508179A JP6240063B2 (ja) | 2011-04-28 | 2012-04-30 | ヒストンデアセチラーゼ阻害剤 |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2014508179A Division JP6240063B2 (ja) | 2011-04-28 | 2012-04-30 | ヒストンデアセチラーゼ阻害剤 |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019185842A Division JP7042244B2 (ja) | 2011-04-28 | 2019-10-09 | ヒストンデアセチラーゼ阻害剤 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2018070614A JP2018070614A (ja) | 2018-05-10 |
| JP2018070614A5 true JP2018070614A5 (enExample) | 2018-09-20 |
| JP6974120B2 JP6974120B2 (ja) | 2021-12-01 |
Family
ID=47072809
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2014508179A Active JP6240063B2 (ja) | 2011-04-28 | 2012-04-30 | ヒストンデアセチラーゼ阻害剤 |
| JP2017212845A Active JP6974120B2 (ja) | 2011-04-28 | 2017-11-02 | ヒストンデアセチラーゼ阻害剤 |
| JP2019185842A Active JP7042244B2 (ja) | 2011-04-28 | 2019-10-09 | ヒストンデアセチラーゼ阻害剤 |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2014508179A Active JP6240063B2 (ja) | 2011-04-28 | 2012-04-30 | ヒストンデアセチラーゼ阻害剤 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019185842A Active JP7042244B2 (ja) | 2011-04-28 | 2019-10-09 | ヒストンデアセチラーゼ阻害剤 |
Country Status (5)
| Country | Link |
|---|---|
| US (5) | US9365498B2 (enExample) |
| EP (2) | EP2701699B1 (enExample) |
| JP (3) | JP6240063B2 (enExample) |
| CA (1) | CA2834548C (enExample) |
| WO (1) | WO2012149540A1 (enExample) |
Families Citing this family (48)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2553337Y2 (ja) | 1993-06-30 | 1997-11-05 | 住友重機械工業株式会社 | 電気集塵装置 |
| EP2701699B1 (en) | 2011-04-28 | 2019-10-16 | The Broad Institute, Inc. | Inhibitors of histone deacetylase |
| JP6337255B2 (ja) | 2012-07-27 | 2018-06-06 | ザ ブロード インスティテュート, インコーポレーテッドThe Broad Institute, Inc. | ヒストンデアセチラーゼの阻害剤 |
| WO2014047199A1 (en) * | 2012-09-19 | 2014-03-27 | The Research Foundation For The State University Of New York | Novel prodrugs for selective anticancer therapy |
| US9914717B2 (en) | 2012-12-20 | 2018-03-13 | The Broad Institute, Inc. | Cycloalkenyl hydroxamic acid derivatives and their use as histone deacetylase inhibitors |
| KR20150100814A (ko) | 2012-12-21 | 2015-09-02 | 콴티셀 파마슈티컬스, 인크. | 히스톤 데메틸라제 억제제 |
| US9139583B2 (en) | 2013-02-01 | 2015-09-22 | Acetylon Pharmaceuticals, Inc. | Selective HDAC3 inhibitors |
| JP2016511237A (ja) | 2013-02-01 | 2016-04-14 | アセチロン ファーマシューティカルズ インコーポレイテッドＡｃｅｔｙｌｏｎ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ，Ｉｎｃ． | 選択的ｈｄａｃ３阻害剤 |
| CN105658643B (zh) * | 2013-08-27 | 2019-03-01 | 百时美施贵宝公司 | Ido抑制剂 |
| NZ728120A (en) | 2014-06-25 | 2023-06-30 | Celgene Quanticel Res Inc | Histone demethylase inhibitors |
| WO2015200619A1 (en) * | 2014-06-26 | 2015-12-30 | Rodin Therapeutics, Inc. | Inhibitors of histone deacetylase |
| JP6556146B2 (ja) | 2014-08-26 | 2019-08-07 | 武田薬品工業株式会社 | 複素環化合物 |
| JP6785801B2 (ja) * | 2015-03-06 | 2020-11-18 | コロラド ステート ユニバーシティー リサーチ ファウンデーション | 新しいキャップ基ラルガゾールの類似体の合成及び使用 |
| AU2016229324B2 (en) | 2015-03-06 | 2020-01-16 | Colorado State University Research Foundation | Method for preparing largazole analogs and uses thereof |
| LT3319959T (lt) * | 2015-07-06 | 2021-12-27 | Alkermes, Inc. | Histono deacetilazės hetero-halogeno inhibitoriai |
| WO2017007755A1 (en) * | 2015-07-06 | 2017-01-12 | Rodin Therapeutics, Inc. | Heterobicyclic n-aminophenyl-amides as inhibitors of histone deacetylase |
| WO2017014321A1 (en) | 2015-07-17 | 2017-01-26 | Takeda Pharmaceutical Company Limited | Oxadiazole derivatives useful as hdac inhibitors |
| WO2017014170A1 (ja) | 2015-07-17 | 2017-01-26 | 武田薬品工業株式会社 | 複素環化合物 |
| US10406146B2 (en) | 2015-08-25 | 2019-09-10 | Takeda Pharmaceutical Company Limited | Heterocyclic compound |
| WO2017100623A1 (en) | 2015-12-09 | 2017-06-15 | Brandeis University | Dbh inhibitors for treating or preventing memory loss |
| RU2018126187A (ru) * | 2015-12-17 | 2020-01-20 | Массачусетс Инститьют Оф Текнолоджи | Композиции полигидроксилированных бензофенонов и способы лечения нейродегенеративных расстройств |
| MX386258B (es) | 2016-07-01 | 2025-03-18 | Pfizer | Derivados de 5,7-dihidro-pirrolo-piridina para tratar enfermedades neurologicas y neurodegenerativas |
| US10894768B2 (en) | 2016-08-26 | 2021-01-19 | Dong-A St Co., Ltd. | Salt of (R)-(1-methylpyrrolidine-3-yl)methyl(3′-chloro-4′-fluoro-[1,1′-biphenyl]-2-yl)carbamate and crystal form thereof |
| KR102239776B1 (ko) * | 2016-08-26 | 2021-04-13 | 동아에스티 주식회사 | (r)-(1-메틸피롤리딘-3-일)메틸(3'-클로로-4'-플루오로-[1,1'-비페닐]-2-일)카바메이트의 신규염 및 이의 결정형 |
| US10793567B2 (en) * | 2017-01-11 | 2020-10-06 | Rodin Therapeutics, Inc. | Bicyclic inhibitors of histone deacetylase |
| JP7442439B2 (ja) | 2017-03-30 | 2024-03-04 | アルベルト－ルートヴィヒ－ユニバーシティー フライブルク | Ｋｄｍ４阻害剤 |
| EP3661931A1 (en) | 2017-07-31 | 2020-06-10 | Takeda Pharmaceutical Company Limited | Heterocyclic compound |
| EA039417B1 (ru) | 2017-08-07 | 2022-01-25 | Родин Терапеутикс, Инк. | Бициклические ингибиторы гистондеацетилазы |
| EP3664789B1 (en) | 2017-08-09 | 2023-11-22 | Children's Hospital Medical Center | Methods for treating diseases and nerve injury |
| EA037772B1 (ru) * | 2017-09-07 | 2021-05-20 | Родин Терапеутикс, Инк. | Бициклические ингибиторы деацетилазы гистонов |
| KR20190043437A (ko) | 2017-10-18 | 2019-04-26 | 씨제이헬스케어 주식회사 | 단백질 키나제 억제제로서의 헤테로고리 화합물 |
| US12128018B2 (en) | 2018-01-12 | 2024-10-29 | KDAc Therapeutics, Inc. | Combination of a selective histone deacetylase 3 (HDAC3) inhibitor and an immunotherapy agent for the treatment of cancer |
| WO2019235501A1 (ja) * | 2018-06-06 | 2019-12-12 | 塩野義製薬株式会社 | ヒストン脱アセチル化酵素阻害剤 |
| EA202190077A1 (ru) * | 2018-07-13 | 2021-08-30 | Алкермес, Инк. | Ингибиторы гистондеацетилазы |
| AU2019301761A1 (en) * | 2018-07-13 | 2021-01-14 | Alkermes, Inc. | Bicyclic inhibitors of histone deacetylase |
| KR102195348B1 (ko) | 2018-11-15 | 2020-12-24 | 에이치케이이노엔 주식회사 | 단백질 키나제 억제제로서의 신규 화합물 및 이를 포함하는 약제학적 조성물 |
| WO2020168241A1 (en) * | 2019-02-15 | 2020-08-20 | Flagship Pioneering Inc. | X-reactivation modulators and uses thereof |
| WO2020176513A1 (en) * | 2019-02-25 | 2020-09-03 | Emory University | Chimeric compounds and methods of managing neurological disorders or conditions |
| AU2020291460B2 (en) * | 2019-06-13 | 2026-01-29 | Dana-Farber Cancer Institute, Inc. | HDAC3 catalytic inhibitor development and uses thereof |
| US20220267323A1 (en) * | 2019-07-23 | 2022-08-25 | Alkermes, Inc. | Synthesis of bicyclic inhibitors of histone deacetylase |
| KR20220070465A (ko) | 2019-09-27 | 2022-05-31 | 다케다 야쿠힌 고교 가부시키가이샤 | Hdac6 억제제로서 유용한 2-이소인돌-1,3,4-옥사디아졸 유도체 |
| EP4074700A4 (en) | 2019-12-10 | 2024-02-07 | Shionogi & Co., Ltd | HISTONE DEACETYLASE INHIBITOR COMPRISING AROMATIC HETEROCYCLIC GROUP CONTAINING NITROGEN |
| CA3186083A1 (en) | 2020-08-14 | 2022-02-17 | Remy LUTHRINGER | Condensed azacycles as sigma ligand compounds and uses thereof |
| JP2023547040A (ja) * | 2020-09-24 | 2023-11-09 | エヌフレクション セラピューティクス インコーポレイテッド | ピロロピリジン－アニリン化合物による、認知機能不全の処置方法 |
| AU2021410630A1 (en) | 2020-12-21 | 2023-08-03 | Cetya Therapeutics, Inc. | Synthesis of structural analogs of largazole and associated compounds |
| CN114957132A (zh) * | 2021-02-20 | 2022-08-30 | 中国科学院上海药物研究所 | 含s构型的氨基苯甲酰胺基哒嗪酮类化合物、其制备方法、药物组合物及应用 |
| CN120344242A (zh) * | 2022-11-07 | 2025-07-18 | 人福医药美国公司 | 生长抑素受体亚型4(sstr4)激动剂和其应用 |
| WO2024230794A1 (zh) * | 2023-05-11 | 2024-11-14 | 中国药科大学 | 氮杂环丁烷衍生物、其制备方法及其医药用途 |
Family Cites Families (121)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE670584C (de) * | 1936-07-09 | 1939-01-20 | I G Farbenindustrie Akt Ges | Verfahren zur Herstellung von o-Aminophenolen |
| DE1108213B (de) | 1959-02-28 | 1961-06-08 | Frantisek Sorm Dr Ing | Verfahren zur Herstellung von 2, 2-Dimethyl-3-phenylcyclopropan-carbonsaeuren |
| SE370866B (enExample) * | 1968-03-21 | 1974-11-04 | Ciba Geigy Ag | |
| JPS4825500B1 (enExample) * | 1970-12-29 | 1973-07-30 | ||
| US3850931A (en) | 1971-06-25 | 1974-11-26 | American Home Prod | 4-(substituted anilino)-2-phenyl-5-pyrimidinecarboxylic acid esters |
| GB2079480B (en) | 1980-07-08 | 1984-05-16 | Kodak Ltd | Heat-activated photographic and thermal recording processes employing precursor compounds |
| NO156828C (no) * | 1980-11-10 | 1987-12-02 | Otsuka Pharma Co Ltd | Analogifremgangsm te for fremstilling av antibakterielt virksomme benzoheterocykliske forbindelser. |
| JPS57102887A (en) | 1980-12-18 | 1982-06-26 | Otsuka Pharmaceut Co Ltd | Preparation of benzo(ij)quinolizine-2-carboxylic acid derivative |
| US4404356A (en) | 1981-09-09 | 1983-09-13 | Ciba-Geigy Corporation | Heat-curable epoxide resin compositions |
| JPS5853916A (ja) | 1981-09-09 | 1983-03-30 | チバ−ガイギ−・アクチエンゲゼルシヤフト | 熱硬化性エポキシド樹脂組成物 |
| US5525727A (en) | 1982-05-18 | 1996-06-11 | University Of Florida | Brain-specific drug delivery |
| DE3511110A1 (de) * | 1985-03-27 | 1986-10-02 | Dr. Karl Thomae Gmbh, 7950 Biberach | Neue pyridazinone, ihre herstellung und diese verbindungen enthaltende arzneimittel |
| GB8508588D0 (en) | 1985-04-02 | 1985-05-09 | Akzo Nv | Indene & napthalene derivatives |
| NZ219974A (en) | 1986-04-22 | 1989-08-29 | Goedecke Ag | N-(2'-aminophenyl)-benzamide derivatives, process for their preparation and their use in the control of neoplastic diseases |
| IT1231413B (it) * | 1987-09-23 | 1991-12-04 | Angeli Inst Spa | Derivati dell'acido benzimidazolin-2-osso-1-carbossilico utili come antagonisti dei recettori 5-ht |
| US5994392A (en) | 1988-02-26 | 1999-11-30 | Neuromedica, Inc. | Antipsychotic prodrugs comprising an antipsychotic agent coupled to an unsaturated fatty acid |
| DE3830054A1 (de) | 1988-09-03 | 1990-03-15 | Boehringer Mannheim Gmbh | Phenylamide - verfahren zu ihrer herstellung sowie diese verbindungen enthaltende arzneimittel |
| JPH03232868A (ja) * | 1990-02-05 | 1991-10-16 | Nippon Telegr & Teleph Corp <Ntt> | 新規光学活性化合物及び液晶組成物 |
| US5177064A (en) | 1990-07-13 | 1993-01-05 | University Of Florida | Targeted drug delivery via phosphonate derivatives |
| AU643141B2 (en) | 1991-03-15 | 1993-11-04 | Amgen, Inc. | Pulmonary administration of granulocyte colony stimulating factor |
| JPH06122669A (ja) | 1991-12-28 | 1994-05-06 | Ishihara Sangyo Kaisha Ltd | ジアミノベンゼン誘導体を含有するホスホリパーゼａ２阻害剤 |
| DE4323916A1 (de) * | 1993-07-16 | 1995-01-19 | Basf Ag | Substituierte 2-Phenylpyridine |
| US5451569A (en) | 1994-04-19 | 1995-09-19 | Hong Kong University Of Science And Technology R & D Corporation Limited | Pulmonary drug delivery system |
| EP0809492A4 (en) * | 1995-02-17 | 2007-01-24 | Smithkline Beecham Corp | IL-8 RECEPTOR ANTAGONISTS |
| US5635503A (en) * | 1995-06-07 | 1997-06-03 | Bristol-Myers Squibb Company | Dihydropyridine npy antagonists: piperazine derivatives |
| US5855887A (en) | 1995-07-25 | 1999-01-05 | The Regents Of The University Of California | Blockade of lymphocyte down-regulation associated with CTLA-4 signaling |
| US5811097A (en) | 1995-07-25 | 1998-09-22 | The Regents Of The University Of California | Blockade of T lymphocyte down-regulation associated with CTLA-4 signaling |
| US6051227A (en) | 1995-07-25 | 2000-04-18 | The Regents Of The University Of California, Office Of Technology Transfer | Blockade of T lymphocyte down-regulation associated with CTLA-4 signaling |
| JPH09227495A (ja) * | 1996-02-16 | 1997-09-02 | Tanabe Seiyaku Co Ltd | フェノール誘導体及びその製法 |
| WO1999000121A1 (en) | 1997-06-26 | 1999-01-07 | Eli Lilly And Company | Antithrombotic agents |
| EE05627B1 (et) | 1998-12-23 | 2013-02-15 | Pfizer Inc. | CTLA-4 vastased inimese monoklonaalsed antikehad |
| JP4390024B2 (ja) | 1999-04-23 | 2009-12-24 | アステラス製薬株式会社 | 新規なジアゼパン誘導体又はその塩 |
| US6653309B1 (en) | 1999-04-26 | 2003-11-25 | Vertex Pharmaceuticals Incorporated | Inhibitors of IMPDH enzyme technical field of the invention |
| NZ517202A (en) | 1999-08-24 | 2004-05-28 | Medarex Inc | Human CTLA-4 antibodies and their uses |
| US7605238B2 (en) | 1999-08-24 | 2009-10-20 | Medarex, Inc. | Human CTLA-4 antibodies and their uses |
| US6713454B1 (en) | 1999-09-13 | 2004-03-30 | Nobex Corporation | Prodrugs of etoposide and etoposide analogs |
| EP1261376A1 (en) | 2000-01-27 | 2002-12-04 | Genetics Institute, LLC | Antibodies against ctla4(cd152), conjugates comprising same, and uses thereof |
| FR2805741B1 (fr) * | 2000-03-06 | 2003-06-20 | Oreal | Composition de teinture d'oxydation des fibres keratiniques avec un derive particulier de la paraphenylenediamine et un colorant direct particulier |
| EP1280764B1 (en) * | 2000-03-24 | 2010-11-24 | Methylgene, Inc. | Inhibitors of histone deacetylase |
| DE10038007A1 (de) * | 2000-08-04 | 2002-02-14 | Bayer Ag | Neue Amino-und Amido-Diphenylether für Arzneimittel |
| US20020173507A1 (en) | 2000-08-15 | 2002-11-21 | Vincent Santora | Urea compounds and methods of uses |
| US6645990B2 (en) * | 2000-08-15 | 2003-11-11 | Amgen Inc. | Thiazolyl urea compounds and methods of uses |
| ATE448306T1 (de) | 2000-09-01 | 2009-11-15 | Blood Res Center | Veränderte, in gewünschter konformation stabilisierte polypeptide und verfahren zu deren herstellung |
| WO2002046172A2 (en) | 2000-12-07 | 2002-06-13 | Cv Therapeutics, Inc. | Substituted 1, 3, 5-triazines and pyrimidines as abca-1 elevating compounds against coronary artery disease or atherosclerosis |
| JP4183923B2 (ja) | 2001-03-29 | 2008-11-19 | 富士フイルム株式会社 | 熱現像感光材料 |
| CA2442557C (en) * | 2001-04-12 | 2008-12-23 | F. Hoffmann-La Roche Ag | Dihydro-benzo¬b|¬1,4|diazepin-2-one derivatives as mglur2 antagonists ii |
| AR034897A1 (es) * | 2001-08-07 | 2004-03-24 | Hoffmann La Roche | Derivados n-monoacilados de o-fenilendiaminas, sus analogos heterociclicos de seis miembros y su uso como agentes farmaceuticos |
| US6949542B2 (en) | 2002-02-06 | 2005-09-27 | Hoffman-La Roche Inc. | Dihydro-benzo[b][1,4]diazepin-2-one derivatives |
| TWI319387B (en) | 2002-04-05 | 2010-01-11 | Astrazeneca Ab | Benzamide derivatives |
| IL164287A0 (en) | 2002-04-12 | 2005-12-18 | Medarex Inc | Methods of treatment using ctla-4 antibodies |
| EP1402888A1 (en) * | 2002-09-18 | 2004-03-31 | Jerini AG | The use of substituted carbocyclic compounds as rotamases inhibitors |
| US7244751B2 (en) | 2003-02-14 | 2007-07-17 | Shenzhen Chipscreen Biosciences Ltd. | Histone deacetylase inhibitors of novel benzamide derivatives with potent differentiation and anti-proliferation activity |
| BRPI0407587A (pt) | 2003-02-18 | 2006-02-14 | Pfizer | inibidores do vìrus da hepatite c, composições e tratamentos que os utilizam |
| WO2005025557A1 (en) | 2003-09-16 | 2005-03-24 | Monash University | An agent for plasminogen-activation and matrix metalloproteinase associated conditions and methods of use |
| WO2005030704A1 (en) | 2003-09-24 | 2005-04-07 | Methylgene, Inc. | Inhibitors of histone deacetylase |
| EP1687513B1 (en) | 2003-10-02 | 2010-12-22 | Jesel, Inc. | Double roller cam follower |
| WO2005034880A2 (en) | 2003-10-09 | 2005-04-21 | Aton Pharma, Inc. | Thiophene and benzothiophene hydroxamic acid derivatives |
| US20080070954A1 (en) | 2003-10-27 | 2008-03-20 | S*Bio Pte Ltd. | Acylurea Connected And Sulfonylurea Connected Hydroxamates |
| WO2005066151A2 (en) | 2003-12-19 | 2005-07-21 | Takeda San Diego, Inc. | Histone deacetylase inhibitors |
| WO2006001958A2 (en) | 2004-05-21 | 2006-01-05 | Merck & Co., Inc. | Amino cyclopentyl heterocyclic and carbocyclic modulators of chemokine receptor activity |
| US20060008517A1 (en) | 2004-07-09 | 2006-01-12 | Lynch Marina A | Treatment of age-related memory impairment |
| CN101001851B (zh) | 2004-08-09 | 2011-04-20 | 安斯泰来制药有限公司 | 具有作为组蛋白脱乙酰酶(hdac)抑制剂的活性的羟基酰胺化合物 |
| JPWO2006028161A1 (ja) * | 2004-09-09 | 2008-05-08 | 財団法人乙卯研究所 | セロトニン５−ｈｔ３受容体作動薬 |
| EP1896395B1 (en) | 2005-06-24 | 2015-07-15 | Merck Sharp & Dohme Corp. | Modified malonate derivatives |
| EA019344B1 (ru) | 2005-07-01 | 2014-03-31 | МЕДАРЕКС, Эл.Эл.Си. | Человеческие моноклональные антитела против лиганда-1 запрограммированной гибели клеток (pd-l1) и их применения |
| AU2007208495A1 (en) | 2006-01-12 | 2007-08-02 | Merck Sharp & Dohme Corp. | Hydroxyalkylarylamide derivatives |
| WO2007118137A1 (en) * | 2006-04-07 | 2007-10-18 | Methylgene Inc. | Benzamide derivatives as inhibitors of histone deacetylase |
| EP2121626A1 (en) | 2006-12-15 | 2009-11-25 | Pfizer Products Inc. | Benzimidazole derivatives |
| EP2099771A1 (en) | 2006-12-19 | 2009-09-16 | Genentech, Inc. | Pyrimidine kinase inhibitors |
| CA2673870A1 (en) | 2006-12-27 | 2008-07-10 | Emory University | Compositions and methods for the treatment of infections and tumors |
| CN101730703B (zh) | 2007-03-16 | 2012-12-26 | 中国人民解放军军事医学科学院放射与辐射医学研究所 | 具有抗增殖活性的苯甲酰胺类衍生物及其药用制剂 |
| JP5191537B2 (ja) | 2007-06-18 | 2013-05-08 | エム・エス・ディー・オス・ベー・フェー | ヒトのプログラムされたデスレセプターｐｄ−１に対する抗体 |
| WO2009002534A1 (en) | 2007-06-26 | 2008-12-31 | Gilead Colorado, Inc. | Imidazopyridinyl thiazolyl histone deacetylase inhibitors |
| US8389553B2 (en) * | 2007-06-27 | 2013-03-05 | Merck Sharp & Dohme Corp. | 4-carboxybenzylamino derivatives as histone deacetylase inhibitors |
| US8138168B1 (en) * | 2007-09-26 | 2012-03-20 | Takeda Pharmaceutical Company Limited | Renin inhibitors |
| MX2010004402A (es) | 2007-10-22 | 2010-10-15 | Orchid Res Lab Ltd | Inhibidores de histona deacetilasa. |
| EP2217588A4 (en) | 2007-11-02 | 2013-12-04 | Methylgene Inc | INHIBITORS OF HISTONE DEACETYLASE |
| WO2009076234A2 (en) | 2007-12-07 | 2009-06-18 | University Of Maryland, Baltimore | Synthesis methods of histone deacetylase inhibitors (hdacis) |
| US8138138B2 (en) | 2008-01-04 | 2012-03-20 | Ecolab Usa Inc. | Solidification matrix using a polycarboxylic acid polymer |
| UA103018C2 (uk) | 2008-02-22 | 2013-09-10 | Оцука Фармасьютікал Ко., Лтд. | Сполуки бензодіазепіну і фармацевтична композиція |
| US8093000B2 (en) | 2008-05-09 | 2012-01-10 | The Regents Of The University Of California | Methods for predicting and treating tumors resistant to drug, immunotherapy, and radiation |
| WO2010009139A2 (en) | 2008-07-14 | 2010-01-21 | Gilead Colorado, Inc. | Imidazolyl pyrimidine inhibitor compounds |
| US20110178138A1 (en) | 2008-07-28 | 2011-07-21 | The Regents Of The University Of California | Inhibitors of protein prenyltransferases |
| US8119129B2 (en) | 2008-08-01 | 2012-02-21 | Bristol-Myers Squibb Company | Combination of anti-CTLA4 antibody with dasatinib for the treatment of proliferative diseases |
| RS54233B1 (sr) | 2008-08-25 | 2015-12-31 | Amplimmune Inc. | Kompozicije pd-1 antagonista i postupci za njihovu primenu |
| CA2735593C (en) | 2008-09-03 | 2017-08-15 | Repligen Corporation | Compositions including 6-aminohexanoic acid derivatives as hdac inhibitors |
| BRPI0919377A2 (pt) | 2008-09-26 | 2016-09-27 | Dana Farber Cancer Inst Inc | anticorpo isolado ou um fragmento ligante de antígeno do memso, ácido nucleico isolado, vetor, célula hospedeira, composição farmacêutica, método de produzir o referido anticorpo ou fragmento, uso dos mesmos, e composição compreendendo o referido anticorpo ou fragmento |
| WO2010042433A1 (en) | 2008-10-06 | 2010-04-15 | Bristol-Myers Squibb Company | Combination of cd137 antibody and ctla-4 antibody for the treatment of proliferative diseases |
| US8232409B2 (en) * | 2008-10-15 | 2012-07-31 | Janssen Pharmaceutica N.V. | Heterocyclic benzimidazoles as TRPM8 modulators |
| NZ593447A (en) | 2008-12-03 | 2012-12-21 | Harvard College | Inhibition of hdac2 to promote memory |
| HUE065752T2 (hu) | 2008-12-09 | 2024-06-28 | Hoffmann La Roche | Anti-PD-L1 antitestek és felhasználásuk T-sejt funkció elõsegítésére |
| ES2629337T3 (es) | 2009-02-09 | 2017-08-08 | Inserm - Institut National De La Santé Et De La Recherche Médicale | Anticuerpos contra PD-1 y anticuerpos contra PD-L1 y usos de los mismos |
| WO2010094678A1 (en) * | 2009-02-23 | 2010-08-26 | F. Hoffmann-La Roche Ag | Novel ortho-aminoamides for the treatment of cancer |
| US8211901B2 (en) | 2009-05-22 | 2012-07-03 | Shenzhen Chipscreen Biosciences Ltd. | Naphthamide derivatives as multi-target protein kinase inhibitors and histone deacetylase inhibitors |
| CN102459249A (zh) * | 2009-05-22 | 2012-05-16 | 埃克塞里艾克西斯公司 | 作为PI3K/mTOR抑制剂的苯并氧氮杂环庚三烯以及它们使用与制造方法 |
| CN102803246A (zh) | 2009-06-11 | 2012-11-28 | 锡耶纳生物技术股份公司 | Hedgehog途径拮抗剂及其治疗应用 |
| JP2012533569A (ja) * | 2009-07-16 | 2012-12-27 | ヴァーテックス ファーマシューティカルズ、 インコーポレイテッド | フラビウイルス感染症を治療又は予防するためのベンゾイミダゾール類似体 |
| IN2012DN03807A (enExample) * | 2009-10-30 | 2015-08-28 | Massachusetts Inst Technology | |
| EP2504028A4 (en) | 2009-11-24 | 2014-04-09 | Amplimmune Inc | SIMULTANEOUS INHIBITION OF PD-L1 / PD-L2 |
| US8952037B2 (en) * | 2010-05-13 | 2015-02-10 | Amgen Inc. | Heteroaryloxycarbocyclyl compounds as PDE10 inhibitors |
| US20140107166A1 (en) | 2011-02-14 | 2014-04-17 | Dana-Farber Cancer Institute, Inc. | Histone deacetylase inhibitors and methods of use thereof |
| RU2013140975A (ru) | 2011-02-28 | 2015-04-10 | Дженентек, Инк. | Биологические маркеры и способы прогнозирования восприимчивости к антагонистам в-клеток |
| EP3524324A1 (en) | 2011-02-28 | 2019-08-14 | BioMarin Pharmaceutical Inc. | Histone deacetylase inhibitors |
| US8957066B2 (en) | 2011-02-28 | 2015-02-17 | Biomarin Pharmaceutical Inc. | Histone deacetylase inhibitors |
| EP2701699B1 (en) | 2011-04-28 | 2019-10-16 | The Broad Institute, Inc. | Inhibitors of histone deacetylase |
| CN102775356B (zh) | 2011-05-13 | 2015-07-22 | 江苏恒谊药业有限公司 | 4-氨基喹唑啉衍生物及其应用 |
| US20130071403A1 (en) | 2011-09-20 | 2013-03-21 | Vical Incorporated | Synergistic anti-tumor efficacy using alloantigen combination immunotherapy |
| WO2013059582A2 (en) | 2011-10-20 | 2013-04-25 | Nupotential, Inc. | Small molecule inhibitors of histone deacteylases |
| EP2773653A4 (en) | 2011-11-02 | 2015-08-05 | Broad Inst Inc | FLUORESCENT SUBSTRATES FOR DETERMINING THE ACTIVITY OF A LYSIN-MODIFYING ENZYME |
| CA2759407A1 (en) | 2011-12-02 | 2013-06-02 | Marrett Alexander GREEN | Grey water recycling systems and valves |
| CN104159911A (zh) | 2012-03-07 | 2014-11-19 | 奥瑞基尼探索技术有限公司 | 作为免疫调节剂的模拟肽化合物 |
| US9212224B2 (en) | 2012-05-15 | 2015-12-15 | Bristol-Myers Squibb Company | Antibodies that bind PD-L1 and uses thereof |
| JP6337255B2 (ja) | 2012-07-27 | 2018-06-06 | ザ ブロード インスティテュート, インコーポレーテッドThe Broad Institute, Inc. | ヒストンデアセチラーゼの阻害剤 |
| US9914717B2 (en) | 2012-12-20 | 2018-03-13 | The Broad Institute, Inc. | Cycloalkenyl hydroxamic acid derivatives and their use as histone deacetylase inhibitors |
| US9988343B2 (en) | 2013-11-05 | 2018-06-05 | Dana-Farber Cancer Institute, Inc. | Inhibitors of histone deacetylase |
| EP3114109A4 (en) | 2014-03-07 | 2017-10-18 | The Johns Hopkins University | Inhibitors of histone lysine specific demethylase (lsd1) and histone deacetylases (hdacs) |
| UY36351A (es) | 2014-10-14 | 2016-06-01 | Novartis Ag | Moléculas de anticuerpo que se unen a pd-l1 y usos de las mismas |
| CN115925939A (zh) | 2015-08-06 | 2023-04-07 | 新加坡科技研究局 | IL2Rβ/通用γ链抗体 |
| TWI794171B (zh) | 2016-05-11 | 2023-03-01 | 美商滬亞生物國際有限公司 | Ｈｄａｃ抑制劑與ｐｄ-ｌ１抑制劑之組合治療 |
| US12440451B2 (en) | 2017-01-10 | 2025-10-14 | Dana-Farber Cancer Institute, Inc. | Compositions and methods using an epigenetic inhibitor |
| US12128018B2 (en) | 2018-01-12 | 2024-10-29 | KDAc Therapeutics, Inc. | Combination of a selective histone deacetylase 3 (HDAC3) inhibitor and an immunotherapy agent for the treatment of cancer |
-
2012
- 2012-04-30 EP EP12775936.3A patent/EP2701699B1/en active Active
- 2012-04-30 CA CA2834548A patent/CA2834548C/en active Active
- 2012-04-30 JP JP2014508179A patent/JP6240063B2/ja active Active
- 2012-04-30 WO PCT/US2012/035814 patent/WO2012149540A1/en not_active Ceased
- 2012-04-30 EP EP13194971.1A patent/EP2712655B1/en active Active
-
2013
- 2013-10-28 US US14/065,278 patent/US9365498B2/en active Active
- 2013-10-28 US US14/065,276 patent/US9447030B2/en active Active - Reinstated
-
2016
- 2016-05-05 US US15/147,201 patent/US9890172B2/en active Active
- 2016-08-11 US US15/234,675 patent/US11572368B2/en active Active
-
2017
- 2017-10-17 US US15/786,134 patent/US10662199B2/en active Active
- 2017-11-02 JP JP2017212845A patent/JP6974120B2/ja active Active
-
2019
- 2019-10-09 JP JP2019185842A patent/JP7042244B2/ja active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2018070614A5 (enExample) | ||
| JP2020023528A5 (enExample) | ||
| JP2021105032A5 (enExample) | ||
| JP2020514318A5 (enExample) | ||
| JP2019509276A5 (enExample) | ||
| JP2007538024A5 (enExample) | ||
| JP2016513661A5 (enExample) | ||
| JP2018188483A5 (enExample) | ||
| JP2015511609A5 (enExample) | ||
| JP2011513420A5 (enExample) | ||
| JP2010500376A5 (enExample) | ||
| JP2020507589A5 (enExample) | ||
| JP2006523216A5 (enExample) | ||
| JP2018522861A5 (enExample) | ||
| JP2018537535A5 (enExample) | ||
| JP2016534063A5 (enExample) | ||
| JP2019510027A5 (enExample) | ||
| JP2019520344A5 (enExample) | ||
| JP2019515884A5 (enExample) | ||
| JP2019516739A5 (enExample) | ||
| JP2020503341A5 (enExample) | ||
| RU2011117927A (ru) | Карбаматное соединение или его соль | |
| JP2020504156A5 (enExample) | ||
| RU2006124863A (ru) | Трициклические производные индолгидроксиэтиламина и их применение при лечении болезни альцгеймера | |
| JP2019529460A5 (enExample) |